Fennec Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Fennec Pharmaceuticals Inc FENC.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of five analysts for the quarter was for earnings of 17 cents per share. Wall Street expected results to range from -19 cents to $1.31 per share.

• Revenue fell 18.6% to $7.93 million from a year ago; analysts expected $16.72 million.

• Fennec Pharmaceuticals Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $1.62 million.

• Fennec Pharmaceuticals Inc shares had risen by 8.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 837.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $13.00

This summary was machine generated from LSEG data March 10 at 02:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)